Possibility of intensification of antiviral therapy of chronic hepatitis B (HBV)with intradermal immunization with inactivated autoleukocytes has been investigated. It was also taken into consideration that autoleukocytes may be used as an individual virus-containing material (“personified vaccine”).

Patients with HBV were immunized thrice with the interval 30-40 days in long-lasting (over 2 years) antiviral therapy with tenofovir, however, DNA HBV replication continued (further reduction of viral load ceased). In a group of 8 patients, DNA HBV of whom constituted ≥3х10⁴ IU/ml, it became less 1000 IU/ml in 5 (62.5%) patients, and in 3 (37.5%) it was detected with only supersensitive PCR method (sensitivity 5 IU/ml). In 16 patients of the second group, DNA HBV amount of whom was ≤ 2 х 10³ IU/ml, in 11 (68.75%) the virus was detected only with supersensitive PCR method, in 5 patient (31.25%) – it was not revealed anymore. In 6 patients of the third group, in whom HBV DNA was detected only with supersensitive PCR method, in 2 – the result became negative (33.33%). Stability of the effect persisted for a year (period of monitoring). Thus, autoleukocyte immunization significantly intensifies efficacy of antiviral HBV therapy.

Biography:
HerasunOlexandrBorysovych was born in 1977; in 2000 graduated from Lviv medical university, in 2000-2001 – intern, 2001-2003 – clinical residency at the department of infectious diseases; worked as a doctor of Lviv regional center of HIV/AIDS; since January 2004 – an assistant at the department of infectious diseases; in 2007 defended PhD research paper on the theme “Clinical-epidemiological and immunopathogenic peculiarities of HBe-negative HBV-DNA-positive chronic hepatitis B”; participated in international programs of investigation of chronic hepatitis and HIV-infections; since 2015 – an associate professor; conducts classes and delivers lectures to students and doctors of the faculty of postgraduate education; has 81 publications.